1. Pioglitazone improves deficits of Fmr1-KO mouse model of Fragile X syndrome by interfering with excessive diacylglycerol signaling
- Author
-
Andréa Geoffroy, Julie Zumsteg, Hervé Moine, Boglarka Zambo, Laetitia Fouillen, Laetitia Schramm, Karima Habbas, Dimitri Heintz, Jean-Louis Mandel, Eric Flatter, Arnaud Duchon, Yann Herault, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)
- Subjects
medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,[SDV]Life Sciences [q-bio] ,RNA-binding protein ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Loss function ,030304 developmental biology ,Diacylglycerol kinase ,0303 health sciences ,business.industry ,Lipid signaling ,medicine.disease ,FMR1 ,3. Good health ,nervous system diseases ,Fragile X syndrome ,Endocrinology ,lipids (amino acids, peptides, and proteins) ,business ,Pioglitazone ,030217 neurology & neurosurgery ,Homeostasis ,medicine.drug - Abstract
Fragile X syndrome (FXS), the leading cause of familial intellectual disability, is an uncured disease caused by the absence or loss of function of the FMRP protein. FMRP is an RNA binding protein that controls the translation of specific proteins in neurons. A main target of FMRP in neurons is diacylglycerol kinase kappa (DGKk) and the loss of FMRP leads to a loss of DGK activity causing a diacylglycerol excess in the brain. Excessive diacylglycerol signaling could be a significant contributor to the pathomechanism of FXS. Here we tested the contribution of DAG-signaling inFmr1-KO mouse model of FXS and we show that pioglitazone, a widely prescribed drug for type 2 diabetes, has ability to correct excessive DAG signaling in the brain and rescue behavioral alterations of theFmr1-KO mouse. This study highlights the role of lipid signaling homeostasis in FXS and provides arguments to support the testing of pioglitazone for treatment of FXS.
- Published
- 2020